Most SCLC cases demonstrate a loss of cyclin dependent kinase inhibitor 2A (CDKN2A) with mutations in TP53 and RB1, a loss of PTEN and activation of PI3K [11,12]. The gene discussed is CDKN2A; the disease is small cell lung carcinoma.